Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis

Recruiting N/A Interventional Study
Spondyloarthritis, Axial Fatigue Exercise Capacity
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
122 (estimated)
Sponsor
University Hospital, Strasbourg, France · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences. Fatigue is a major feature of SA. It can be defined as a feeling of reduced muscle capacity, lack of energy and exhaustion. The fatigue reaches an abnormally high level (fatigue severity score (FSS) ≥4, called severe fatigue in this protocol) in mo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * Axial SA according to the ASAS criteria; * Targeted therapy naïve patients * Indication to start a targeted therapy; * Initiation of targeted therapy ≤ 15 days before inclusion * ≥ 18 years old, no upper age limit; * Subject affiliated to a social health insurance reimbursemen…
Contacts

Alain MEYER, MD

+33 3 88 11 67 68

alain.meyer1@chru-strasbourg.fr

CONTACT